A single 3 mg subcutaneous dose produced greater than 90% peripheral B-cell depletion in most participants, including two participants with B cells below the limit of detection, with B-cell reductions persisting
Initial clinical data from the Phase 1 healthy-volunteer study of JANX011 to be presented during an investor webcast on November 9, 2026
First patient dosed in the Phase 1 study evaluating JANX013 in combination
Virtual event to be held on Monday, November 9, 2026, at 8:30 a.m. ETJanux Therapeutics, Inc. (NASDAQ:JANX), a clinical-stage biopharmaceutical company developing next-generation immunotherapies, today announced that it
- JANX013 is a novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific designed to further enhance the durability of anti-tumor immune responses in combination with Janux’s PSMA-targeted T cell engager
JANX007 Phase 1b enrollment continues across taxane-naïve monotherapy and darolutamide combination cohorts
JANX014 Phase 1 study continues enrolling patients with metastatic castration-resistant prostate cancer
JANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide
Initiated clinical evaluation of JANX014, a double-masked PSMA-TRACTr candidate
JANX011
Janux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue further clinical development of
-JANX014 expands Janux's PSMA tumor-activated T cell engager portfolio
-JANX007 is the Company's lead prostate cancer program and primary development priority
-JANX013, a PSMA-TRACIr CD28 co-stimulatory program,
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development candidate under its
Continued clinical execution across TRACTr programs JANX007 and JANX008
JANX007 enrolling in Phase 1b Taxane-naïve patient population in metastatic castration-resistant prostate cancer (mCRPC)
JANX008 enrolling
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first participant has been dosed in a Phase 1
Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator
Janux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor
Phase 1 data demonstrates durable responses and rPFS coupled with a manageable safety profile
rPFS of 7.9-8.9 months in heavily pre-treated mCRPC patients
Preliminary results are encouraging with deep PSA
